WO2005084694A1 - インフルエンザウイルス感染抑制剤 - Google Patents
インフルエンザウイルス感染抑制剤 Download PDFInfo
- Publication number
- WO2005084694A1 WO2005084694A1 PCT/JP2004/003031 JP2004003031W WO2005084694A1 WO 2005084694 A1 WO2005084694 A1 WO 2005084694A1 JP 2004003031 W JP2004003031 W JP 2004003031W WO 2005084694 A1 WO2005084694 A1 WO 2005084694A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- peptide
- influenza virus
- binding
- phage
- influenza
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- the present invention relates to an influenza virus infection inhibitor comprising a sialylgalactose group-binding peptide, for example, a gandaliside GM3-binding peptide as an active ingredient.
- Oligosaccharides of glycoconjugates such as glycolipids, glycoproteins and proteodalicans on the cell surface are target molecules for the recognition of extracellular molecules and are involved in cell-specific binding processes (1). ), (2)).
- the sialylgalactose (NeuAc-Gal) structure is well known as a receptor for bacterial toxins, viruses, endothelial cells and the like (References (3)-(5)).
- Daricosphingolipids with sialic acid, so-called gandariosides have been implicated in important biological functions, which depend on their carbohydrate moieties (6)-(8).
- glycosphingolipids were extracted from cells as detergent-insoluble membranes together with signaling molecules (13)-(15). Glycolipid-rich subfractions have been found to be modified by cell stimulation and signaling.
- the glycolipid-containing membrane was reconstituted as an air-water interface monolayer (Refs. (16)-(18)). Sato et al. Reported that the mode of lectin binding depends on the distribution of glycosphingolipids in lipid monolayers (References (19)-(22)).
- glycolipid-rich microdomains in cell membranes will help define the biological role of sugar chains on the cell surface.
- a biological selection system (phage display library) was developed to select peptides that specifically bind to target molecules (Refs. (25), (26)).
- Various sugar conjugates, monosaccharides (References (27), (28)), tumor-associated saccharide antigens (References (29)-(32)), Cyaryl Lewis x (References (33), (34)), Glycosui It was performed on Ngoi lipids (Refs. (35), (36)), proteodalican (Refs. (37)-(39)), and polysaccharides (Refs. (40), (41)).
- the present inventors selected a gandarioside GMl (Gal j3 l ⁇ 3GalNAc ⁇ 1 ⁇ 4 (NeuAc 2 ⁇ 3) Gal ⁇ l ⁇ 4Glc / 3 1 ⁇ 1 ′ Cer) binding peptide. (Ref. (35)). It was shown that the selected peptide sequence specifically bound to GM1 and inhibited the binding of cholera toxin to GM1.
- Influenza virus membranes contain two types of glycoproteins, hemagglutinin (HA) and sialidase (neuraminidase), which are important for the establishment of virus infection and budding of virus from host cells, respectively. Plays a role. Hemagglutinin recognizes a sialic acid-containing sugar chain present on the cell membrane of an animal host as a receptor, specifically binds, and leads to endocytosis of influenza virus into cells.
- Sialidase is a receptor-destroying enzyme that cleaves sialic acid residues from itself or on host cell membranes when virus particles germinate or release from host cells.
- sialidase inhibitors are thought to inhibit the influenza virus from growing outside the cell and then releasing it out of the cell. Yes. Therefore, sialidase inhibitors had no effect as prophylactics, and had to be administered 1 to 2 days after infection with the influenza virus, and their application was limited.
- influenza virus binds to hemagglutinin and a sialic acid-containing sugar chain present in a host cell during infection with the influenza virus
- the present inventor has previously described HA (hemagglutinin) binding using the phage display library method described above. And reported that the peptide inhibits influenza infection by preventing influenza virus from invading cells (Japanese Patent Laid-Open No. 2002-284798, W00 / 59932). It has been shown that peptides can be used to prevent infection with influenza virus. Disclosure of the invention
- the present invention relates to an agent for suppressing infection with influenza virgils, which comprises, as an active ingredient, a sialylgalactose group-binding peptide that binds to a sialylgalactose group (a group having a sialic acid-galactose structure).
- influenza virus is infected by the hemagglutinin of the viral membrane that recognizes and binds to sialic acid-containing sugar chains of the host cell.
- An object of the present invention is to block a receptor for hemagglutinin present in a host cell and to suppress influenza virus infection. Specifically, the purpose is to inhibit influenza virus infection by blocking the binding of influenza virus to host cells using a peptide that binds to sialylgalactose groups present on the cell surface. I do.
- hemagglutinin-binding peptides that bind to influenza virus hemagglutinin can suppress influenza virus infection.
- the peptide binds to the hemagglutinin present on the membrane of the influenza virus, and thereby binds to the influenza virus. Inhibits virus binding to host cells.
- Hemagglutinin-binding peptides can act against influenza virus to prevent infection, but are premised on the presence of influenza virus. Therefore, when it is actually used in clinical practice, it is considered effective to confirm the influenza virus infection as well as the sialidase inhibitor before administration, and it is more effective as a therapeutic drug than as a preventive drug. The effect is expected.
- the present inventors believe that a compound that acts on a living body can be administered regardless of influenza infection and exerts a great preventive effect.Thus, the present inventors have conducted intensive studies on a method for suppressing infection with influenza virus. It was thought that by blocking the receptor of host cells to which hemagglutinin present in the membrane of influenza virus binds, infection with influenza virus can be suppressed.
- the present inventors focused on the structure of sialyl galactose, which is a receptor on the surface of influenza virus host cells, and found that gandariosides GM3 (NeAc2 ⁇ 3Gal ⁇ l ⁇ 4GlcjS We examined the effect of a peptide with more than 10 amino acid residues that binds to 1 ⁇ ⁇ Cer).
- the present inventors obtained a peptide that binds to gandarioside GM3 by using a mouse B16 melanoma cell that highly expresses gandarioside GM3 on the cell surface by a phage display method using a random peptide library.
- the present inventors have obtained the gandarioside GM3 linkage.
- the present inventors have conducted intensive studies on PT / JP2004 / 003031 sex peptides, and have surprisingly found that the peptides alone prevent influenza from binding to receptors on the cell surface and preventing influenza from entering the cells. It was completed.
- the present invention is as follows.
- influenza virus infection inhibitor which comprises the following sialylgalactose group-binding peptide (a) or (b) as an active ingredient:
- [4] The influenza virus infection inhibitor according to any one of [1] to [3], wherein the sialylgalactose group-binding peptide is alkylated or lipidated,
- influenza virus infection according to any one of [1] to [3], wherein the peptide having a sialylgalactose group-binding peptide is contained in the ribosome; [6] the influenza virus is influenza A, influenza B and C [1] any of the agents for controlling influenza virus infection according to any of [1],
- influenza virus is avian influenza or swine influenza; [1] the influenza virus infection inhibitor according to any of [5];
- influenza virus infection inhibitor according to any of [1] to [7], further comprising a pharmaceutically acceptable carrier.
- [10] a method of preventing or treating influenza according to [9], wherein the non-human animal is a bird or a pig;
- [11] A method for preventing or treating influenza, comprising preparing the inhibitor of influenza virus according to any one of [8] and administering the inhibitor to a subject.
- [1 2] The method of preventing or treating influenza according to [1 1], wherein the subject is selected from the group consisting of human, bird and bush,
- a peptide comprising an amino acid sequence in which one or several amino acids are deleted, substituted or added in the amino acid sequence represented by SEQ ID NO: 1 or 2, and which has ganglioside GM3 binding activity;
- FIG. 1 is a diagram showing the time course of phage binding to a gandarioside GM3 monolayer immobilized on a quartz crystal microbalance.
- FIG. 2 is a diagram showing the results of an examination of the binding selectivity of a phage clone to the NeuAc-Gal structure.
- FIG. 3 is a diagram showing the results of examination of binding of a phage clone to mouse B16 melanoma cells by flow cytometry.
- FIG. 4 is a diagram showing the results of examination of recognition of sialyl oligosaccharides by cOl phage.
- Figure 5 shows the amount of synthetic peptide bound to GM3 as a function of peptide concentration.
- FIG. 6 shows inhibition of influenza virus infection of MDCK cells by peptide-containing ribosomes.
- FIG. 7 is a diagram showing inhibition of infection of influenza virus into MDCK cells by ganglioside GM3-binding peptide-containing ribosome and hemagglutinin-binding peptide-containing ribosome.
- the present invention is an infection-suppressing agent containing a sialylgalactose group, for example, a ganglioside GM3-binding peptide as an active ingredient, which can be used for prevention and treatment of influenza virus infection.
- a sialylgalactose group for example, a ganglioside GM3-binding peptide as an active ingredient, which can be used for prevention and treatment of influenza virus infection.
- a sialylgalactose group having a structure in which sialic acid and galactose are bound serves as a receptor for hemagglutinin when the influenza virus enters the cell. By preventing binding to the cell via the cell group, influenza can be prevented from infecting the cell.
- the compound having a sialylgalactose group includes, for example, ganglioside GM3, and the sialylgalactose group-binding peptide of the present invention includes a gandarioside GM3-binding peptide.
- the peptide of the present invention is not limited as long as it binds to the sialylgalactose group.Therefore, if the sialylgalactose group is expressed on the surface of the cell, even if the ganglioside GM3 is not expressed on the surface. Infection of the cells with the influenza virus can be suppressed.
- the influenza virus which suppresses infection with the infection suppressant of the present invention is a globular RNA virus having a diameter of about 100 nm belonging to the family Orsomicsviridae, and its type is not limited. Since the influenza virus inhibitor of the present invention blocks the receptor recognized by influenza in cells, it can suppress infection regardless of the type of influenza virus.
- Influe PT / JP2004 / 003031 A type of virus (H2N2, H3N2, H1N1, etc.), B type, C type, human isolated type, avian isolated type (avian influenza virus (H5N1, H7N2, H7N7, etc.)) It can widely suppress infection with influenza viruses such as swine isolates (Buyu influenza virus) and other mammalian isolates such as horses. Depending on the flu types of hemagglutinin and sialidase (neuraminidase), many subtypes exist depending on the influenza virus, but the influenza virus infection inhibitor of the present invention can be used in any type or subtype. However, infection with the influenza virus can be suppressed.
- influenza virus inhibitor of the present invention can be used for any animal that can be infected with an influenza virus, and can suppress infection of humans, birds, busines, etc. with the influenza virus. Can be.
- the sialylgalactose group-binding peptide of the present invention can be selected by a phage display library method using a known phage display library as follows.
- the phage display library method can be performed by, for example, the method of Scott and Smith (Scott, JM and Smith, GP, Science, 249. 386-390 (1990); Smith, GP and Scott, JK, Method s in Enzymology, 217, 228-257 (1993)). Further, it can be carried out according to the description in JP-A-2000-253900 and JP-A-2002-284798.
- a commercially available phage display library can be used.
- a phage is constructed by inserting a random DNA sequence into a known phage display library so that a peptide having a random amino acid sequence can be expressed on the outer surface of the phage.
- a peptide having random 15 amino acids on the surface of the phage shell, in which random DNA has been inserted into the phage coat protein piII gene is expressed.
- display phage constructed as 2004/003031 Yes By using the display phage, the phage can be obtained that expressed the about 108 kinds of peptidase flop tides respectively.
- the phage that randomly expresses the peptide is panned using gandarioside GM3.
- a monolayer of gandarioside GM3 may be prepared on a suitable substrate (Gandarioside GM3 monolayer cumulative substrate), and phages that bind to the monolayer may be selected.
- the selected phages are infected with Escherichia coli and cultured in large quantities, separated and purified to obtain peptide-expressing phages that bind to gandariosides GM3.
- a phage capable of expressing a peptide capable of specifically binding to gandarioside GM3 can be selected and concentrated.
- a peptide that specifically binds to the sialylgalactose group expressed by the phage can be obtained.
- the DNA sequence may be determined by the known Maxam-Gilbert method or the like, and a commercially available sequencer may be used.
- a monomolecular film when used, only a sugar chain protrudes from the surface, so that a peptide having a sialylgalactose group-binding property can be efficiently selected.
- a crystal oscillator known as microbalance can be used.
- a change in weight of the surface of the quartz oscillator gold electrode caused by the binding of the phage can be detected as a change in frequency.
- a method using a crystal oscillator is described, for example, in Bioch im. Biophys.
- a sialylgalactose group-binding peptide is a gandarioside GM3-binding peptide consisting of 15 amino acids shown in SEQ ID NOS: 1 and 2.
- the present invention also relates to a peptide comprising an amino acid sequence in which one or several amino acids are deleted, substituted or added in the amino acid sequence represented by SEQ ID NO: 1 or 2, and which can bind to gandaliside GM3. It can be used as an active ingredient of the influenza virus inhibitor of the present invention.
- the “one or several” is preferably one or ten, more preferably one or five, one or four, one or three, one or two or one.
- Peptides that bind to ganglioside GM3 can also be used as an active ingredient of the influenza virus inhibitor of the present invention.
- the stringent condition means, for example, that after performing hybridization at 68 ° C in the presence of 0.7 to 1.0 M NaCl using a filter on which DNA is immobilized, 0.1 A condition that can be identified by washing at 68 ° C using a ⁇ 2x concentration SSC solution (1x concentration SSC is composed of 150 mM NaCl, 15 mM sodium citrate).
- a peptide comprising an amino acid sequence encoded by a degenerate mutant of DNA encoding the peptide consisting of the amino acid sequence represented by SEQ ID NO: 1 or 2, which binds to gandarioside GM3. It can be used as an active ingredient of the influenza virus inhibitor of the present invention.
- Whether or not the peptide binds to gandarioside GM3 can be determined by using, for example, the above-described quartz resonator to which the ganglioside monomolecular film is attached.
- the above-mentioned peptide can be synthesized by a known liquid phase method and solid phase method peptide synthesis method. It can also be prepared using the selected phage and E. coli.
- the peptide thus obtained is a known peptide Can be purified by using the purification method described above.
- a peptide obtained by modifying the ganglioside GM3-binding peptide can also be used.
- the peptide modification increases hydrophilicity, increases blood half-life, and can increase cell affinity and tissue affinity. Therefore, the effect as an inhibitor of influenza infection can be expected.
- by modifying the peptide into a polymer by modification the binding of influenza virus to gandarioside GM3 is sterically hindered, and the effect as an inhibitor can be expected.
- Examples of the peptide modification include binding of a water-soluble polymer such as alkylation, lipidation, and PEGylation.
- the binding of the alkyl group can be carried out by a known method.
- an alkylamine may be bound to the C-terminal carboxyl group of the gandarioside GM3-binding peptide, or a fatty acid may be bound to the N-terminal amino group.
- the binding of the alkylamine to the terminal lipoxyl group or the binding of the fatty acid to the terminal amino group can be carried out by an amide bond forming reaction.
- the alkyl group to be bonded is not limited, but includes an alkyl group having 2 to 20 carbon atoms, for example, an alkyl group having 18 carbon atoms.
- the fatty acid used for binding the fatty acid is not limited, but a fatty acid existing in the living body can be suitably used, and specifically, a saturated fatty acid such as lauric acid, myristic acid, palmitic acid, stearic acid, and araquinic acid.
- Lipidation of the ganglioside GM3-binding peptide can also be performed by a known method. For example, New Current, 11 (3), 15-20 (2000); Biochemica et Biophysica Acta., 1128, 44-49 (1992); FEBSLetters, 413, 177-180 (1997); J. Biol. Chem., 257. , 286-288 (1982).
- a ganglioside GM3-binding peptide can be bound via the 2-position hydroxyl group or the 3-position phosphate group of various phospholipids. This At the time of 4 003031, they may be linked via an appropriate spacer.
- Various condensation methods can be employed for the reaction.
- an amino acid sequence containing about several cysteines of an appropriate length is bound to the N-terminal or C-terminal of the ganglioside GM3-binding peptide, and a reactive SH group is used.
- the phospholipid used is not limited, and examples thereof include phosphatidic acid, phosphatidylcholine (lecithin), phosphatidylethanolamine, phosphatidylserine, phosphatidylinositol, phosphatidylglycerol, and the like.
- a lipidated peptide is called a lipopeptide.
- water-soluble polymer examples include polyethylene glycol, monomethoxypolyethylene dalicol, dextran, poly (N-vinylpyrrolidone) polyethylene glycol, and propylene glycol homopolymer. Propylene oxide / ethylene oxide copolymer, polyvinyl alcohol and the like. These polymers can be covalently linked to the N-terminal ⁇ -amino group of the protein and the ⁇ -amino group of lysine via a reactive group such as an aldehyde. Among them, PEG is preferable, and the molecular weight of PEG is preferably 6 kDa to 50 kDa.
- dendrimerization is one of the methods for polymerizing the gandarioside GM3-binding peptide.
- a ribosome preparation containing a ganglioside GM3-binding peptide can also be used as the inhibitor of influenza infection of the present invention.
- “Liposome” means a membrane-like closed vesicle composed of a lipid layer and a water layer in the membrane.
- the ribosome preparation of the present invention can be prepared by adding a ganglioside GM3-binding peptide to the ribosome.
- Ribosomes include liposomes containing acidic phospholipids as membrane components or liposomes containing neutral phospholipids and acidic phospholipids as membrane components.
- acidic phospholipids as membrane constituents include dilauroyl phos P2004 / 003031 Fatidylglycerol (DLPG), dimyris doylphosphatidylglycerol (DMPG), dipalmitoylphosphatidylglycerol (DPPG), distearoylphosphatidylglycerol (DSPG), dioleoylphosphatidylglycerol (DOPG), yolk phosphatidyl Natural or synthetic phosphatidyl glycerols (PG) such as glycerol (egg yolk PG), hydrogenated yolk phosphatidyl glycerol, and dilauryl phosphatidylinositol (DLPI); dimyristyl phosphatidylinositol (DMPI); (DPP 1), distearoyl phosphatidylinositol (DSPI), dioleoyl phosphatidylinosito
- the neutral phospholipids include soybean phosphatidylcholine, egg yolk phosphatidylcholine, hydrogenated soybean phosphatidylcholine, hydrogenated egg yolk phosphatidylcholine, dimyristoytylphosphatidylcholine (DMP C), dipalmitylphosphatidylcholine (DPPC), Dilauroyl phosphatidyl choline (DLPC), distearoyl phosphatidyl choline (DSPC), myristyl palmitoyl phosphatidyl choline (MPPC), palmitoyl stearoyl phosphatidyl choline (PSPC), dioleoyl phosphatidyl choline (DOPC), etc.
- DMP C dimyristoytylphosphatidylcholine
- DPPC dipalmitylphosphatidylcholine
- DLPC Dilauroyl phosphatidyl choline
- DSPC distea
- Natural or synthetic phosphatidylcholines PC
- soy phosphatidylethanolamine egg yolk phosphatidylethanolamine, hydrogenated soybean phosphatidylethanolamine, hydrogenated yolk phosphatidylethanolamine , Jimi squirrel toyl phosphatidylethanolamine ⁇ Min (DMP E), Jiparumi toyl phosphatidylethanolamine no Ruamin (DPPE), dilauroyl phosphatidylethanolamine ⁇ Min (DLPE), distearoylphosphatidylethanolamine ⁇ Min (DSPE), Natural or synthetic phosphatidylethanolamines (PE) such as myristoyl palmitoylphosphatidylethanolamine (MPPE), palmitoylstearoylphosphatidylethanolamine (PSPE), and dioleoylphosphatidylethanolamine (DOPE); No. These constituents may be used alone or in a combination of two or more.
- MPPE myristoyl palmitoylphosphati
- Ribosomes containing the ganglioside GM3-binding peptide can be prepared according to a known method using the above phospholipids.
- the ratio of the acidic phospholipid is about 0.1 to 100 mol%, preferably about 1 to 90 mol%, more preferably about 10 to 50 mol% in the ribosome membrane component. It is better to do.
- cholesterol and the like may be further added.
- cholesterol By adding cholesterol, the fluidity of the phospholipids can be adjusted to make the preparation of ribosomes easier.
- Cholesterol is usually added and blended in an amount equivalent to the phospholipid, preferably in an amount of 0.5 to 1 equivalent.
- the mixing ratio of the ganglioside GM3-binding peptide and the acidic phospholipid in the liposomal dispersion is about 0.5 to 100 equivalents, preferably about 1 to 60 equivalents of the acidic phospholipid to the peptide. And more preferably about 1.5 to 20 equivalents.
- the proportion of the ganglioside GM3-binding peptide contained in the ribosome is about several mol% to several tens mol%, preferably about 5 to 30 mol%, and more preferably about 5 to 10 mol% of the total lipid. It is.
- the ribosome preparation of the present invention containing the ganglioside GM3-binding peptide can be produced by a known method.
- a multilayer ribosome is prepared as follows. First, after dissolving the lipid in an organic solvent (such as black form and ether), put it in a round-bottom flask, remove the organic solvent under a nitrogen stream or under reduced pressure, and remove Create a thin film of lipid on the bottom. In this case, it is possible to completely remove the organic solvent by leaving the mixture under desiccation overnight. Next, an emulsion-colored ribosome suspension is obtained by adding a drug solution onto a lipid thin film to hydrate the lipid.
- an organic solvent such as black form and ether
- L UV Large single-walled ribosomes
- Ca "to small single-walled ribosomes of phosphatidylserine fusing them into a cylindrical sheet, and adding EDTA, a chelating agent.
- Method for removing Ca 2+ (Biochim. Biophys. Acta 394, 483-491, 1975) Injecting lipid dissolved in a polyester into an aqueous solution at about 60 ° C and evaporating ether (Biochim. Biophys. Biophys. Acta 443, 629-634, 1976).
- a method for preparing ribosomes by the reverse phase method devised by Szoka et al. can be used.
- a WZO emulsion is prepared by adding a drug solution to a phospholipid ether solution and subjecting the solution to ultrasonic treatment. After removing the ether from the WZO emulsion under reduced pressure using an evaporator, then adding a buffer solution and stirring with a Portex mixer, the WZO emulsion was converted into an ozw emulsion, and the remaining organic solvent was further removed. By removing it, ribosomes can be created.
- liposomes with a small particle size can be prepared by the French press method (FEBS lett. 99. 210-214, 1979).
- the freeze-drying method (Chem. Pharm. Bull. 31, 2442-2445, 1984) and the freeze-thaw method (Chem. Pharm. Bull. 33, 2916-) with high retention efficiency to liposomes reported by Osawa et al. 2923, 1985) can also be used.
- the ribosomes prepared in this manner can be used for the dialysis method U. Pharm. Sci. II, 806-812, 1982) or the filtration method using a polycarbonate membrane (Biochim. Biophys. Acta 557, 9-23, 1979; Biochim. Biophys. Acta L 559-571, 1980) can keep the particle size constant.
- dialysis Method, gel filtration method, and centrifugation method can be used (ribosome. "Lipid Chemistry” [edited by Biochemical Society of Japan, Biochemistry Experiment Course 3], Tokyo Chemical Dojin, 1974). It is also possible to concentrate ribosomes using a dialysis membrane.
- the ribosome dispersion prepared in this manner contains various additives such as preservatives, isotonic agents, buffers, stabilizers, solubilizers, absorption promoters, etc., which are required as additives in the formulation design. Can be appropriately compounded, and if necessary, can be diluted with a liquid or water containing these additives.
- additives include preservatives that are effective against fungi and bacteria such as benzalkonium chloride, benzethonium chloride, black hexidine, parabens (methylparaben, ethylparaben, etc.), thimerosal, etc.
- agent examples include polyhydric alcohols such as D-mannitol, D-sorbitol, D-xylitol, glycerin, glucose, maltose, sucrose, propylene glycol, and electrolytes such as sodium chloride, and a stabilizer such as tocopherol. Butylhydroxyanisole, butylhydroxytoluene, ethylenediaminetetraacetate (EDTA), cysteine, etc., respectively.
- polyhydric alcohols such as D-mannitol, D-sorbitol, D-xylitol, glycerin, glucose, maltose, sucrose, propylene glycol, and electrolytes such as sodium chloride, and a stabilizer such as tocopherol.
- Butylhydroxyanisole, butylhydroxytoluene, ethylenediaminetetraacetate (EDTA), cysteine, etc. respectively.
- ribosome comprising the HA-binding peptide of the present invention
- another drug such as an antiviral agent can be further encapsulated, and similarly, a ribosome preparation can be obtained.
- liposome preparations are specifically described in, for example, Woodre et al. (Long Circulating Liposomes: old drugs, New therapeutics., M. Woodle, G. Storm, Eds: Springer-Verlag Berlin (1998))
- Woodre et al. Long Circulating Liposomes: old drugs, New therapeutics., M. Woodle, G. Storm, Eds: Springer-Verlag Berlin (1998)
- it can be prepared according to the method described in Liposomal applications to cancer therapy, Y. Naniba, N. Oku, J. Bioact. Compat. Polymers, 8, 158-177 (1993).
- the above-described alkylated peptide-lipidated peptide can be used as a lipid component.
- the amount of the GM3-binding peptide is not limited, and is appropriately selected depending on the subject to be administered. Usually, the amount is about 0.002 to 0.2 (w / V%) in the composition, preferably about 0 0.01 to 0.1 (wZv%).
- the influenza virus infection inhibitor of the present invention can prevent influenza virus infection when administered to a subject not infected with influenza virus, and can be administered to a subject already infected with influenza virus. Inhibits influenza virus from infecting other cells, and can be used as a therapeutic agent for influenza virus.
- the inhibitor of influenza infection of the present invention contains a ganglioside GM3-binding peptide as an active ingredient, and may further contain a pharmaceutically acceptable carrier, diluent and excipient.
- a pharmaceutically acceptable carrier diluent and excipient.
- purified water sterile water
- a physiological buffer an isotonic solution, or the like
- injectable organic esters such as glycol, glycerol and olive oil can also be used. Gelling agents, lactose, magnesium stearate and the like are used as carriers and excipients for tablets.
- the inhibitor of influenza virus infection of the present invention can be administered in various forms as a pharmaceutical composition.
- administration forms include oral administration by tablets, capsules, granules, powders, syrups and the like, or parenteral administration by injections, drops, suppositories and the like. It can also be administered as a spray.
- a solution containing the influenza virus inhibitor of the present invention may be sprayed orally or nasally onto a subject, and can be efficiently administered to domestic animals such as birds and bush. It is.
- Such a composition is produced by a known method and is usually used in the field of pharmaceuticals.
- the administration route of the inhibitor of influenza virus infection of the present invention is not limited, and includes oral administration, intravenous injection, intramuscular injection, intradermal injection, subcutaneous injection, intraperitoneal injection, spray, and the like.
- influenza virus inhibitor of the present invention is avian, It can also be administered by mixing with water, feed, etc., which are consumed by livestock such as pigs.
- the dose can be appropriately determined depending on the severity of the disease and the like, but a pharmaceutically effective amount of the composition of the present invention is administered to the patient.
- administering a pharmaceutically effective amount refers to administering to a patient a drug at an appropriate level for treating various diseases.
- the frequency of administration of the pharmaceutical composition of the present invention is appropriately selected according to the patient's condition.
- the amount can be generally selected from the range of about 0.001 to 10 Omg per adult day, in terms of the amount of ganglioside GM3-binding peptide.
- the formulation can be administered not only once a day but also several times. When administering to domestic animals such as birds and bush, the dose can be determined appropriately considering the weight and the like.
- influenza virus infection inhibitor of the present invention may contain a compound capable of suppressing infection of another influenza virus as an active ingredient.
- Other compounds include, for example, influenza virus and hemagglutinin-binding peptides described in JP-A-2002-284798, and specifically, for example, JP-A-2002-284798 and 00/59932 There are peptides described. Inclusion of gandarioside GM3-binding peptide and influenza virus-hemagglutinin-binding peptide in influenza virus inhibitors binds to the influenza virus's own cell-binding part and to the cell's influenza virus. Both parts are blocked, and greater influenza virus suppression can be expected.
- influenza virus / hemadaltinin-binding peptide one having a part of amino acids mutated or modified as in the above-mentioned gandarioside GM3-binding peptide can be used. Further, it may be contained in the ribosome.
- the influenza virus infection inhibitor of the present invention is a ribosome preparation
- the ribosome may contain both a gandarioside GM3-binding peptide and an influenza virus / hemagglutinin-binding peptide.
- Gandarioside GM3 (NeuAca 2 ⁇ 3Gal ⁇ l ⁇ 4Glc) 31 ⁇ ⁇ Cer) was obtained from Snow Brand Milk Products (Japan).
- 6 ′ GM3 (NeuAc 2 ⁇ 6Gal j81 ⁇ 4G1C J31 ⁇ ⁇ Cer) which is a synthetic GM3 analog was prepared by the method described in the literature (42).
- Lactosyl ceramide (LacCer), galactosyl ceramide (GalCer) and darcocerebuloside (GlcCer) were purchased from Sigma (St Louis, MO, USA).
- Yolk phosphatidylcholine (egg PC) and cholesterol were obtained from N0F and nacalai tesQiie (Japan), respectively.
- the phage display 15-mer random peptide library (10 8 diversity) was obtained as described in reference (43).
- the 15-mer peptide amide (peptide-NH 2 ) and N-stearoyl (octadecanoyl) peptide amide (C 17 H 35 C0-peptide-NH 2 ) were obtained from Advanced Chemtech using standard Fmoc methods. Automated peptide synthesizer ACT357.
- Peptideamide and N-stearoyl peptide amide were purified by reversed-phase high-performance liquid chromatography. Next, purity and expected structure were confirmed by MALDI-TOF / MS.
- Mouse B16 melanoma cells were obtained from RIKEN Cell Bank (Japan).
- Madin-Darby canine kidney (MDCK) cells and influenza A / Puerto Rico / 8/34 virus strain (H1N1) were provided by K. Nagata (Tsukuba University, Japan).
- TBS Tris buffered salt solution
- p-A Surface pressure
- GM3 The monolayer is compressed at a constant rate (10 cm 2 min— and a crystal microbalance (QCM: 9 MHz, AT-cut, diameter 4.5 band, area 15.9 mm) at a surface pressure of 30 mN m- 1. It was transferred horizontally to the gold surface of the bandit 2 ) (Reference (21)) QCM was transferred to a handmade plastic tube filled with 1 ml of TBS, and the buffer temperature was maintained at 20 with stirring. Round 6.1-87 x 10 transduction units) were injected into the cuvette. Phage binding to the monolayer (AF, Hz) was followed over time to determine the incubation time.
- QCM 9 MHz, AT-cut, diameter 4.5 band, area 15.9 mm
- the phage clones were isolated, amplified, and precipitated with polyethylene daricol / NaCl (PEG # 6000) [26]
- the DNA of each phage clone was purified using the QIAprep Spin in M13 kit (QIAGEN). It was used as a type I sequence for estimating amino acid alignment.
- Polystyrene multiwell plates were pre-blocked with 1% BSA / TBS and washed three times.
- a plastic plate (13.5 mm in diameter, Sumitomo BeiKit, Japan) was horizontally bonded to the Gandarioside GM3 or 6 'GM3 monolayer prepared as described above. Phage clones (0.01-10 nM in 2001 TBS) were incubated with the monolayer at 4 for 30 minutes. The other side of the plastic plate was blocked by adding 0.5% BSA / TBS, and then washed twice with 0.5% BSA / TBS.
- Bound phages were incubated with l: 2000 (v / v) diluted anti-id pacteriophage (Sigma) at 4 h for 1 hour, followed by l: 2000 (v / v) diluted anti-peregis immunoglobulin G peroxidida Using one zekkondigate 4 Labeled for 1 hour. Color was developed with o-phenylenediamine and detected at 492 nm. Each experiment was performed three times. The increase in absorbance ( ⁇ A at 492 nm) shows a simple saturation curve against phage concentration, which has a linear relationship as a plot between [phage] / ⁇ and [phage] as in the following equation: showed that.
- the maximum absorbance ( ⁇ Amax) and dissociation constant (K d ) were calculated from the slope and intercept of the equation, respectively. K d was in the range from 0.018 to 0.09 InM.
- the AAmax of the control phage was also evaluated each time, and the relative binding affinity ( ⁇ Amax / ⁇ Aax, control) was evaluated (Table 1). The wild type of phage was used as control. '
- Mouse B16 melanoma was obtained from Dulbecco's modified Eagle's medium (ICN Biomedicals) supplemented with 10% fetal serum (Life Technologies, Inc.), 100 units / ml of penicillin G, and 100 units / ml of streptomycin. ) 37 ° C in, were grown under conditions of 53 ⁇ 4C0 2> 95% air.
- Glycolipids (GM3, 6'GM3, LacCer, GalCer, or GlcCer) monolayer are prepared on the rung Muir type aquarium, QCM (27MHz, AT- cut, diameter 2.5 thigh, the plane product 4.9 Yuzuru 2) It was taken horizontally above.
- the 27-MHz QCM has higher sensitivity than 9-MHz (about 10 times) (Refs. (44)-(46)).
- Peptide solutions of 0.1 mM, lmM and lOmM in TBS were added to the cell cuvette of the QCM instrument and the decrease in QCM frequency (AF, Hz) in response to peptide addition was followed over time. Each experiment was performed 2-6 times.
- the peptide sequence that binds to the sugar chain of GM3 was selected by one method of a phage library bound to a lipid monolayer as described in reference (35).
- a GM3 monolayer was prepared at the air-water interface and used for affinity selection.
- GM3-specific phage increased during the four affinity selection process.
- the relative yield of recovered phage increased from 0.2 to 15 ⁇ 10 6 through four rounds of biopanning (data not shown).
- the binding affinity of the selected phage to the GM3 monolayer was confirmed by 9 MHz quartz crystal microbalance (QCM) (References (21)-(22)) o Tris-buffered saline ( ⁇ 50 ⁇ ).
- QCM quartz crystal microbalance
- the frequency decrease (mass increase) of QCM in response to the addition of phage (10 lfl TU / mL) in tris-HCK 150 mM NaCK pH 7.5 was followed over time (FIG. 1).
- FIG. 1 shows the results of the fourth round of phage clones (black circles) for affinity selection using the phage library (open circles) or GM3 monolayer.
- the GM3 monolayer was attached to a 9 MHz QCM gold surface, and the QCM was immersed in 1 ml of Tris-buffered saline at pH 7.5.
- a phage solution containing 6 ⁇ 10 1 ⁇ conversion units was injected into the buffer and the frequency decrease in response to phage binding was plotted against time. From this result, it was found that the final phage concentration was 2 ⁇ .
- the change in frequency indicated that the binding of the selected phage (26 Hz) was 6.5 times that of the original library (4 Hz).
- cOl sequence selected in this study was the same sequence as one of the GM1 binding peptides (GM1 / peptide 2). This is due to the limitations of the diversity of the library, since the same phage library was used. These results suggest that the cOl sequence has a broad affinity for sialic acid-containing glycolipids.
- the ratio of C ⁇ Amax / ⁇ Amax, control D-binding of the phage clone to GM3 was evaluated by ELISA.
- the N-terminal sequence of the control phage clone (wild type) is AETVESCLAKPHTEN.
- the binding affinity of the isolated phage clone to GM3 was assessed by ELISA.
- a GM3 monolayer was prepared at the air-water interface and transferred to a plastic plate. The plastic plate was transferred to a 24-well multiplate and incubated with the phage clone for 30 minutes.
- a saturation curve was obtained by plotting the color development by the enzyme versus the phage concentration, and the maximum absorbance (AAmax) was calculated from Equation I above.
- C01> c03> cl5> c30> c07> c21 cll.
- the relative binding affinity, ie, ( ⁇ of selected phage) Z was between 1.1 and 2.1 (Table 1). The most frequently occurring (15/27) phage clone cOl showed the highest affinity for GM3.
- the binding affinity of the two phage clones cOl and c03 was further examined by ELISA.
- the binding affinity of these clones was determined using GM3 containing NeuAc 2 ⁇ 3Gal linkage and synthetic 6 ′ GM3 containing NeuAc 2 ⁇ 6Gal linkage.
- the cOl clone bound to both GM3 and 6 'GM3 at a magnification of 2.1 and 1.6, respectively, as compared to the control clone ( Figure 2).
- the isolated cOl and c03 phage clones were serially diluted. (0.05-10nM), interacting with GM3 (NeuAc 2 ⁇ 3Gal ⁇ 1 ⁇ 4Glc ⁇ l ⁇ V Cer) or 6 ′ GM3 (NeuAc 2 ⁇ 6Gal j3 l ⁇ 4Glc ⁇ 1 ⁇ ⁇ Cer) monolayer
- GM3 Neurogenase 2 ⁇ 3Gal ⁇ 1 ⁇ 4Glc ⁇ l ⁇ V Cer
- 6 ′ GM3 NeuroAc 2 ⁇ 6Gal j3 l l ⁇ 4Glc ⁇ 1 ⁇ ⁇ Cer
- the amount of bound phage clones was assessed by ELISA.
- the relative binding affinity ( ⁇ Amax / ⁇ Amax control ) indicates the maximum absorbance of the phage clone ( ⁇ ⁇ ⁇ ⁇ Amax) It was obtained by dividing by the maximum absorbance.
- the cOl phage clone was shown to bind to any NeuAc-Gal bond.
- the c03 clone specifically bound to GM3 at a magnification of 1.8 compared to the control clone.
- the c03 phage clone showed a different binding affinity between spliced 2 ⁇ 3 and spliced 2 ⁇ 6 sialic acid to galactose.
- the binding affinity of the phage clones selected for animal cells was examined.
- the B16 cell line mainly expresses GM3, and hardly expresses other gandariosides (13), (15), (49) _ (51).
- Cells were incubated with phage clones and binding clones and labeled with fluorescein-conjugated antibodies. The fluorescence of the cells was measured using a flow cytometer, and the observed fluorescence intensity was plotted as a function of phage concentration ( Figure 3).
- B16 cells were incubated with cOl phadic clone (closed circle), c03 phage clone (open circle) or control phage clone (wild type, closed triangle) in BSA / PBS for 1 hour at 0 ° C. Bound phage clones were labeled with an anti-phage primary antibody and a FITC-conjugated secondary antibody. The amount of phage clone bound to the cells was determined by flow cytometry overnight.
- cOl phage clones are transferred to B16 cells at phage concentrations ranging from 1 to 10 ⁇ . Joined. However, no significant binding was observed for c03 and control phage clones.
- FIG. 4A shows the inhibition of binding between the cOl phage clone and B16 cells by monosaccharides.
- B16 cells (2 ⁇ 10 5 cells) were incubated with phage clones ( ⁇ ) in the absence (-) or presence of NeuAc, Glc or GlcU (lmM).
- GlcU glucuronic acid
- a slight inhibition was observed. Since GlcU is an acidic sugar, like NeuAc, it is likely that carboxylic acids were partially involved in the interaction between phage and sugar chains. On the other hand, depending on the amount of glucose added, the inhibition was unbearable.
- Neuraminidase (sialidase) from the Arthrobacter ureaf aciens et al. Preferentiallyzes the terminal ⁇ 2 ⁇ 3 and ⁇ 2 ⁇ 6 linked sialic acids of glycoconjugates (relative activity is ⁇ 2 ⁇ 6> ⁇ 2 ⁇ 3> ⁇ 2 ⁇ 8) (Reference (52)).
- FIG. 4B shows the effect of neuraminidase treatment on phage binding of B16 cells.
- B16 cells (2 ⁇ 10 5 cells) were incubated with 0.05 units of neuraminidase (pH 6.5) at 37 ° (:, 90 minutes, in 1% BSA / PBS, and further incubated with phage clones.
- Asterisk means p ⁇ 0.05.
- H-GWWYKGRARPVSAVA-NH 2 ( cOl peptide, SEQ ID NO: 1) of the 15-mer peptidyl Puchido preliminary H- RAVWRHSVATPSHSV- negation 2 ( The c03 peptide, SEQ ID NO: 2) was synthesized. Attachment of these peptides to glycolipids was analyzed by the 27-MHz QCM method (27-MHz QCM is about 10 times more sensitive than 9-MHz) (Refs. (44)-(46)). Monolayers of glycolipids (GM3, 6'GM3, LacCer, GalCer or GlcCer) were prepared at the air-water interface and transferred to a QCM gold surface.
- the phage library selection method is used to determine the glycolipid binding peptide sequence in combination with a lipid monolayer at the air-water interface. (Reference (35)).
- glycolipid molecules are highly oriented at a surface pressure of 30 mN m- 1 (0.4 nm 2 mol ecu le, so that only sugar chains are exposed to the aqueous phase.
- GM3 was used as a target molecule for affinity selection because GM3 has a sialylgalactose residue, which is the major oligosaccharide present on the cell surface.
- the GM3-binding phage pool was enriched by four rounds of affinity selection, which was detected by quartz crystal microbalance in each round (data not shown) and ultimately 6. A 5-fold increase in mass was detected (Figure 1) The QCM frequency decrease (26 Hz) observed in the fourth round was thought to correspond to the saturation binding of phage on the QCM electrode.
- the amide group of the peptide further acts as a hydrogen bond donor
- the carbonyl group or carboxylic acid group of the peptide and NeuAc act as a hydrogen bond
- the B-face of the galactopyranose ring and the methyl group of NeuAc correspond to Trp and Phe.
- the consensus motif of the GM3-binding peptide was composed of sugar-binding amino acids. Therefore, these peptides ⁇ defend the NeuAc-Gal moiety by hydrogen bonding and Vander-Pellus interaction.
- the sialylgalactose (NeuAc-Gal) structure is the terminal sugar sequence in glycoproteins and glycolipids.
- B16 cells were used to determine affinity with GM3 on the cell surface of selected phages, since mouse B16 melanoma cells primarily express GM3 and few other gandariosides. (References (13), (15), (49)-(50)). When B16 cells were incubated with the selected phage clones, only the cOl phage clone bound to the cells ( Figure 3). Detachment of sialic acid from the cells and addition of free N-acetyl neuraminic acid resulted in inhibition of phage binding to cells.
- influenza virus infection was determined by plaque assay on MDCK cells.
- the MDCK cells in the 6-well plate Alternatively, the influenza A / PR / 8/34 virus solution containing peptide-containing ribosomes (100-200 pfu, pfu is a plaque-forming unit) was 0.2 mL and incubated. After 5% 37 ° C, 30 min fin incubation under C0 2, the supernatant was removed, cells were washed with PBS. 0.6% Agarosu (0.01% 0-Jefferies chill aminoethyl cellulose de kiss Trang, 0.
- Inhibition of influenza virus infection of MDCK cells by peptide-containing liposomes was determined by plaque assay. Peptides were acylated at the N-terminus using a steer group and incorporated into PC / cholesterol ribosomes (peptide-containing liposomes). Since both the synthetic cOl and c03 peptide had affinity for the NeuAc 2 ⁇ 3Gal and NeuAc 2 ⁇ 6Gal structures, the peptide-containing ribosomes could bind to sialyligosaccharides on MDCK cells. In the presence of the peptide-containing liposome, infection of the MDCK cells with the influenza A / PR / 8/34 virus (H1N1) was inhibited (FIG. 6).
- MDCK cells were incubated with influenza A / PR / 8/34 virus for 30 minutes in the presence of ribosomes containing cOl peptide (closed circles), ribosomes containing c03 peptide (open circles) or ribosomes alone (closed triangles). Cells were washed and incubated for 2 days. The live cells were then stained and the number of blacks counted. IC 5Q values of peptides containing ribosomes cOl and c03 were respectively 0.36 and 0.37 mM (Table 3). The control peptide sequence showed no inhibition. The cO 1 and c03 phage clones did not have an affinity for influenza virus (data not shown).
- pill peptide liposome 20 10: 3 C 17 H 3 sCO-AETVESCI, AKPHTEN- NH 2 > 10
- Ribosome 20 10: 0-> 10
- Similar experiments also included the gandarioside GM3-binding peptides cOl ⁇ peptide and c03 ⁇ peptide and influenza hemagglutinin binding peptide A-1 (ARLSPTMVHPNGAQP (SEQ ID NO: 8)). This was performed using a liposome.
- Figure 7 shows the results. In FIG. 7, the horizontal axis shows the concentration (mM) of eggPC in the ribosome, and the vertical axis shows the infection inhibition rate (%). The infection inhibition rate was expressed as a reduction ratio of the number of plaques when the peptide-containing ribosome was added to the number of plaques when the peptide-free ribosome was added.
- peptide-containing ribosomes inhibited influenza virus (H1N1 type) infection of MDCK cells (FIG. 6).
- the hemagglutinin serotype HI of influenza type A virus A / PR / 8/34 (HIN 1) is specific for NeuAc a ⁇ 3Gal binding.
- MDCK cells have both ⁇ 2 ⁇ 3 and ⁇ 2 ⁇ 6 linked sialic acids on the cell surface (Reference (59)).
- Peptide ribosomes bound to the sialylgalactose portion of MDCK cells and inhibited the binding of influenza virus to the sialylgalactose receptor on MDCK cells. Recently, Takikawa et al.
- a 15mer peptide sequence recognizing the sialylgalactose moiety was obtained by one phage library selection.
- the resulting peptide had affinity not only for the sugar chains of the glycolipid monolayer, but also for the glycoprotein on the cell surface. Binding of the peptide to the cell surface significantly inhibited influenza virus infection.
- the peptides selected in the present invention can be used as inhibitors of influenza virus. The following is a list of documents referred to in the present invention. When the following documents are referred to in this specification, the document numbers are indicated.
- an influenza virus that inhibits binding of an influenza virus to a host cell by blocking a receptor of the host cell.
- An agent for suppressing lus infection is provided.
- the inhibitor of influenza virus infection of the present invention is effective because it blocks the receptor of host cells and can suppress subsequent influenza virus infection even if administered to a subject before influenza virus infection. It can be used as an effective infection preventive agent.
- influenza virus infection inhibitor of the present invention blocks the receptor recognized by influenza virus in cells, so that it can suppress infection regardless of the type of influenza virus, and can suppress influenza virus. It can be used not only for influenza virus isolated from type B humans, but also for infection control of influenza viruses isolated from birds. Furthermore, even after infection with influenza virus, it is possible to suppress the influenza virus that grew by budding from infecting cells again, so that it can be used effectively as a therapeutic agent for influenza virus.
- the active ingredient of the influenza virus inhibitor of the present invention is a peptide consisting of dozens of amino acids, it can be easily synthesized and formulated, and can be used as various forms of pharmaceutical compositions.
- All publications cited herein are incorporated by reference in their entirety. Further, it is easily understood by those skilled in the art that various modifications and alterations of the present invention are possible without departing from the technical concept and the scope of the invention described in the appended claims. Would. The present invention is intended to cover such modifications and variations.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/JP2004/003031 WO2005084694A1 (ja) | 2004-03-09 | 2004-03-09 | インフルエンザウイルス感染抑制剤 |
JP2006510604A JPWO2005084694A1 (ja) | 2004-03-09 | 2004-03-09 | インフルエンザウイルス感染抑制剤 |
US10/592,253 US20090098195A1 (en) | 2004-03-09 | 2004-03-09 | Influenza virus infection suppressor |
CA002559067A CA2559067A1 (en) | 2004-03-09 | 2004-03-09 | Influenza virus infection suppressor |
EP04718765A EP1728515A4 (en) | 2004-03-09 | 2004-03-09 | INHIBITOR OF INFLUENZA VIRUS INFECTION |
CNA2004800427656A CN1938041A (zh) | 2004-03-09 | 2004-03-09 | 流感病毒感染抑制剂 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/JP2004/003031 WO2005084694A1 (ja) | 2004-03-09 | 2004-03-09 | インフルエンザウイルス感染抑制剤 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005084694A1 true WO2005084694A1 (ja) | 2005-09-15 |
Family
ID=34917859
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2004/003031 WO2005084694A1 (ja) | 2004-03-09 | 2004-03-09 | インフルエンザウイルス感染抑制剤 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20090098195A1 (ja) |
EP (1) | EP1728515A4 (ja) |
JP (1) | JPWO2005084694A1 (ja) |
CN (1) | CN1938041A (ja) |
CA (1) | CA2559067A1 (ja) |
WO (1) | WO2005084694A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010024108A1 (ja) * | 2008-08-29 | 2010-03-04 | 学校法人慶應義塾 | インフルエンザウイルス感染症の予防ないし治療剤 |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2411526A4 (en) * | 2009-03-27 | 2012-09-19 | Zacharon Pharmaceuticals Inc | MODULATORS OF GANGLIOSID BIOSYNTHESIS |
US10087226B2 (en) * | 2014-03-11 | 2018-10-02 | Universite D'aix-Marseille | Chimeric peptide that interacts with cell membrane gangliosides |
CN111393512B (zh) * | 2020-03-24 | 2021-03-02 | 北京中科微盾生物科技有限责任公司 | 一种抑制流感病毒的多肽及其在制备预防和治疗流感病毒感染药物中的应用 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH05279379A (ja) * | 1992-03-31 | 1993-10-26 | Snow Brand Milk Prod Co Ltd | ガングリオシドgm3組成物及びその製造法 |
WO1997022615A1 (fr) * | 1995-12-18 | 1997-06-26 | Daikin Industries, Ltd. | Analogues de gangliosides fluores gm3 et leurs intermediaires |
JPH1072355A (ja) * | 1996-08-29 | 1998-03-17 | Snow Brand Milk Prod Co Ltd | インフルエンザウイルス吸着阻止剤 |
JP2000253900A (ja) * | 1999-01-05 | 2000-09-19 | Otsuka Pharmaceut Co Ltd | 糖脂質に結合するペプチドの選別方法 |
WO2000059932A1 (fr) * | 1999-03-31 | 2000-10-12 | Otsuka Pharmaceutical Co., Ltd. | Peptides se liant a l'hemagglutinine du virus de la grippe |
JP2001233773A (ja) * | 2000-02-22 | 2001-08-28 | Toko Yakuhin Kogyo Kk | 抗ウイルス剤 |
JP2002284798A (ja) * | 2001-03-27 | 2002-10-03 | Keio Gijuku | インフルエンザウイルス・ヘマグルチニン結合性ペプチド |
-
2004
- 2004-03-09 EP EP04718765A patent/EP1728515A4/en not_active Withdrawn
- 2004-03-09 US US10/592,253 patent/US20090098195A1/en not_active Abandoned
- 2004-03-09 WO PCT/JP2004/003031 patent/WO2005084694A1/ja active Application Filing
- 2004-03-09 CN CNA2004800427656A patent/CN1938041A/zh active Pending
- 2004-03-09 CA CA002559067A patent/CA2559067A1/en not_active Abandoned
- 2004-03-09 JP JP2006510604A patent/JPWO2005084694A1/ja active Pending
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH05279379A (ja) * | 1992-03-31 | 1993-10-26 | Snow Brand Milk Prod Co Ltd | ガングリオシドgm3組成物及びその製造法 |
WO1997022615A1 (fr) * | 1995-12-18 | 1997-06-26 | Daikin Industries, Ltd. | Analogues de gangliosides fluores gm3 et leurs intermediaires |
JPH1072355A (ja) * | 1996-08-29 | 1998-03-17 | Snow Brand Milk Prod Co Ltd | インフルエンザウイルス吸着阻止剤 |
JP2000253900A (ja) * | 1999-01-05 | 2000-09-19 | Otsuka Pharmaceut Co Ltd | 糖脂質に結合するペプチドの選別方法 |
WO2000059932A1 (fr) * | 1999-03-31 | 2000-10-12 | Otsuka Pharmaceutical Co., Ltd. | Peptides se liant a l'hemagglutinine du virus de la grippe |
JP2001233773A (ja) * | 2000-02-22 | 2001-08-28 | Toko Yakuhin Kogyo Kk | 抗ウイルス剤 |
JP2002284798A (ja) * | 2001-03-27 | 2002-10-03 | Keio Gijuku | インフルエンザウイルス・ヘマグルチニン結合性ペプチド |
Non-Patent Citations (2)
Title |
---|
MATSUBARA T.: "Ganglioside-binding peptides selected from a combinatorial library and their carbohydrate recognition", TRENDS IN GLYCOSCIENCE AND GLYCOTECHNOLOGY, vol. 13, no. 73, 2001, pages 557 - 560, XP002980251 * |
See also references of EP1728515A4 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010024108A1 (ja) * | 2008-08-29 | 2010-03-04 | 学校法人慶應義塾 | インフルエンザウイルス感染症の予防ないし治療剤 |
JPWO2010024108A1 (ja) * | 2008-08-29 | 2012-01-26 | 学校法人慶應義塾 | インフルエンザウイルス感染症の予防ないし治療剤 |
JP5583017B2 (ja) * | 2008-08-29 | 2014-09-03 | 学校法人慶應義塾 | インフルエンザウイルス感染症の予防ないし治療剤 |
Also Published As
Publication number | Publication date |
---|---|
JPWO2005084694A1 (ja) | 2008-01-17 |
CA2559067A1 (en) | 2005-09-15 |
US20090098195A1 (en) | 2009-04-16 |
EP1728515A1 (en) | 2006-12-06 |
EP1728515A4 (en) | 2009-03-18 |
CN1938041A (zh) | 2007-03-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6676589B2 (ja) | 薬物動態特性の改善されたコンプスタチンアナログ | |
Hendricks et al. | Sialylneolacto-N-tetraose c (LSTc)-bearing liposomal decoys capture influenza A virus | |
JP4528989B2 (ja) | インフルエンザウイルス・ヘマグルチニン結合性ペプチド | |
CA2674269C (en) | Three component glycolipopeptides | |
CN111375055B (zh) | 一种2019-nCoV亚单位疫苗组合物及其免疫方法 | |
US8828929B2 (en) | Cytotoxic T cell epitope peptide for SARS coronavirus, and use thereof | |
FI109969B (fi) | Menetelmä fosfolipidikaksikerrosrakkuloiden valmistamiseksi | |
JP2002514892A (ja) | 遺伝子治療における合成ウイルス様粒子の使用 | |
CN101262881A (zh) | 通过交叉β结构的佐剂化 | |
US11267853B2 (en) | Carbohydrate tethering at cell surfaces to induce immune response | |
KR101415864B1 (ko) | 면역학적 활성 조성물 | |
JP4651213B2 (ja) | インフルエンザウイルス・ヘマグルチニン結合性ペプチド | |
JP2022502392A (ja) | 経口剤形の製造方法 | |
US20230256082A1 (en) | Vaccine against human-pathogenic coronaviruses | |
Sedaghat et al. | Synthesis of mannosylated lipopeptides with receptor targeting properties | |
JP5778692B2 (ja) | 疾病抑制剤 | |
WO2005084694A1 (ja) | インフルエンザウイルス感染抑制剤 | |
US20140147476A1 (en) | Organic nanotube having hydrophobized inner surface, and encapsulated medicinal agent prepared using the nanotube | |
KR102017973B1 (ko) | 항-b형 간염 바이러스 x 단백질 폴리펩티드 약제 | |
JP2007145777A (ja) | インフルエンザウイルス感染阻害方法 | |
JP2006101709A (ja) | ヘマグルチニン結合ペプチド、インフルエンザウイルス感染阻害剤、リポソーム、インフルエンザ治療薬、インフルエンザ予防薬 | |
JP5818319B2 (ja) | 脂質膜構造体に細胞透過能を付与および/または脂質膜構造体の細胞透過能を増強するペプチド、ならびにそれらペプチドと結合した脂質を構成脂質として含む、細胞透過能を有するまたは細胞透過能が増強された脂質膜構造体 | |
CN113813375A (zh) | 一种新型抗新冠病毒复合物的组成及其在防治冠状病毒感染疾病药物中的应用 | |
EP4108251A1 (en) | Griffithsin for use in a method of preventing or treating infections with respiratory viruses |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200480042765.6 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2006510604 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2559067 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004718765 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2004718765 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10592253 Country of ref document: US |